SEC Form 4 reporting owner

Lubner David Charles

Lubner David Charles has filed 6 Form 4 transactions reported between January 20, 2026 and August 7, 2026, as Director of Braveheart Bio, Inc., a reporting owner of Dyne Therapeutics, Inc., Director of CRESCENT BIOPHARMA, INC. and a reporting owner of Arcellx, Inc..

Name as filed: Lubner David Charles

Open-market buys, 24 mo

None

reported

Open-market sales, 24 mo

None

reported

Companies

with Form 4 filings

Latest transaction

Aug 7, 2026

transaction date

Roles and reported holdings

BRVEBraveheart Bio, Inc.
Aug 5, 2026 – Aug 7, 2026
Director
No common-stock holding reported on a purchase, sale, gift or withholding line.
1 line is priced far from BRVE’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.
DYNDyne Therapeutics, Inc.
Apr 24, 2026 – Jun 5, 2026
Reporting owner
Held directly0 sh as of Apr 24, 2026 · Form 4
CBIOCRESCENT BIOPHARMA, INC.
Jun 2, 2026
Director
No common-stock holding reported on a purchase, sale, gift or withholding line.
ACLXArcellx, Inc.
Jan 20, 2026
Reporting owner
No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 6 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

Date	Company	Type	Shares	Price	Value	Owned after	Filing
Aug 7, 2026	BRVEDirector	Open-market purchaseCode P · directPrice far from market; may be another security	55,555	$18.00	$1000K@ $18.00	55,555	Form 4
Aug 5, 2026	BRVEDirector	Grant or awardCode A · direct	60,000	—	—	60,000	Form 4
Jun 5, 2026	DYN	Grant or awardCode A · direct	35,152	—	—	35,152	Form 4
Jun 2, 2026	CBIODirector	Grant or awardCode A · direct	11,050	—	—	11,050	Form 4
Apr 24, 2026	DYN	GiftCode G · direct	53,625	—	—	0	Form 4
Jan 20, 2026	ACLX	Option exerciseCode M · direct	6,000	$6.28	$38K@ $6.28	27,659	Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

1 open-market line is priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.